<DOC>
	<DOCNO>NCT00050843</DOCNO>
	<brief_summary>The primary objective study determine efficacy thalidomide treatment anemia patient myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>A Study Access Safety/Efficacy Thalidomide Treatment Anemia Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Eligible patient must diagnosis myelodysplastic syndrome Life expectancy least 6 month . Patients must able adhere study visit schedule protocol requirement . Patients must understand voluntarily sign informed consent document . Women childbearing potential ( WCBP ) must agree practice abstinence use TWO method contraception begin 4 week prior start study medication throughout course treatment . Males must use barrier contraception engage reproductive sexual activity woman childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2004</verification_date>
</DOC>